<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04909905</url>
  </required_header>
  <id_info>
    <org_study_id>17300609</org_study_id>
    <nct_id>NCT04909905</nct_id>
  </id_info>
  <brief_title>Glutamine Supplementation and Short-term Mortality in Covid-19</brief_title>
  <official_title>The Impact of Glutamine Supplementation Upon the Short-term Mortality of COVID-19 Diseased Patients Admitted in ICU: A Double Blind Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effect of parenteral L-Glutamine supplementation&#xD;
      added to enteral nutrition on short-term ICU mortality (7 days) in Covid-19 diseased&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A written informed consent will be taken from the patients or their relatives. Patients with&#xD;
      diagnosis of covid-19 with enteral nutrition will be enrolled. Patients will be randomly&#xD;
      assigned to receive either standard enteral nutrition (Group EN) or intravenous glutamine&#xD;
      supplementation to enteral nutrition (group GN) in a dose of glutamine of 0.4 g/kg/day during&#xD;
      ICU stay.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2021</start_date>
  <completion_date type="Actual">October 30, 2021</completion_date>
  <primary_completion_date type="Actual">October 25, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>7 days</time_frame>
    <description>Short-term ICU mortality for patients admitted in our ICU &amp; signed for study drugs, who will expire during the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutrophil/lymphocyte ratio (NLR)</measure>
    <time_frame>7 days</time_frame>
    <description>Assessing NLR at day zero &amp; day 7 to monitor inflammatory response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D- dimer level</measure>
    <time_frame>7 days</time_frame>
    <description>Assessing D-dimer level at day zero &amp;day 7 to monitor coagulability status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU stay</measure>
    <time_frame>7 days</time_frame>
    <description>Period of patients admission in ICU within duration of study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Group EN (standard enteral nutrition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive standard enteral nutrition according to ICU nutrition protocol during 7days from admission</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group GN (glutamine supplemented enteral nutrition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive intravenous glutamine supplementation to enteral nutrition in a dose of glutamine of 0.4 g/kg/day during 7 days from admission.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Standard enteral nutrition</intervention_name>
    <description>Standard enteral nutrition according to ICU nutrition protocol for 7 days</description>
    <arm_group_label>Group EN (standard enteral nutrition)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Glutamine</intervention_name>
    <description>Intravenous glutamine supplementation to enteral nutrition in a dose of dose of glutamine of 0.4 g/kg/day for 7days</description>
    <arm_group_label>Group GN (glutamine supplemented enteral nutrition)</arm_group_label>
    <other_name>Dipeptiven</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of covid-19 diseased patients admitted to the ICU with enteral nutrition.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal failure (creatinine &gt;180 mmol/l)&#xD;
&#xD;
          -  Hepatic failure (bilirubin &gt;40 mmol/l, alanine aminotransferase &gt;100 U/l and aspartate&#xD;
             aminotransferase &gt;100 U/l)&#xD;
&#xD;
          -  Severe neutropenia (&lt;500 cells/mm3)&#xD;
&#xD;
          -  Patients receiving cytotoxic, radiation and/or steroid therapy&#xD;
&#xD;
          -  Hemodynamic instability&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar Soliman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Omar makram</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Omar Soliman</name>
      <address>
        <city>Assiut</city>
        <state>Assuit</state>
        <zip>Assuit universi</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Mehta S. Nutritional status and COVID-19: an opportunity for lasting change? Clin Med (Lond). 2020 Apr 27. pii: clinmed.2020-0187. doi: 10.7861/clinmed.2020-0187. [Epub ahead of print]</citation>
    <PMID>32341077</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 30, 2021</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Omar Makram Soliman</investigator_full_name>
    <investigator_title>Lecturer of anesthesia and ICU</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

